Copyright ©2023 SMART CAMP
CrossCUT
Crosscut B
Improved manufacturing of CD19 and novel TIM3-targeted CAR-T cells for acute myeloid leukaemia
Purpose
Improved manufacturing of CD19 and novel TIM3-targeted CAR-T cells for acute myeloid leukaemia
Crosscut Captains
While CAR-T therapies are transforming the landscape of cancer treatment, multiple hurdles have limited the impact even of FDA approved therapies. As genetically modified autologous cell therapies, CAR-T treatments are notoriously expensive (often exceeding US$500,000/dose), and are beset with manufacturing challenges. For CAR-T cells to mature as therapies, improvements must be made for the discovery and detection of attributes for potency and safety, sterility testing, control of processes, and time to manufacture. At CAMP, we are working on technologies to improve each aspect of CAR-T manufacturing, from the discovery and detection of functional attributes, to improved testing of adventitious agents, to improved means of growing the cells themselves.
Highlights
Generation Next: New Era of Excellence
PORTFOLIO highlights "Get To Know" individuals, who are ushering a new era of excellence in Singapore
Cancer Cell Therapy: Looking to the Future of CAR T Cell Manufacturing
Manufacturing innovations in CAR T cell therapies could be a game-changer for many late-stage cancer patients.
Publications
Khloe S. Gordon, Taeyoon Kyung, Caleb R. Perez, Patrick V. Holec, Azucena Ramos, Angela Q. Zhang, Yash Agarwal, Yunpeng Liu, Catherine E. Koch, Alina Starchenko, Brian A. Joughin, Douglas A. Lauffenburger, Darrell J. Irvine, Michael T. Hemann & Michael E. Birnbaum
Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains`
2022
SMART CAMP Authors
Connor S Dobson, Anna N. Reich, Stephanie Gaglione, Blake E. Smith, Ellen J. Kim , Jiayi Dong, Larance Ronsard, Vintus Okonkwo, Daniel Lingwood, Michael Dougan , Stephanie K. Dougan & Michael E. Birnbaum
Antigen identification and high throughput interaction mapping by reprogramming viral entry
2022
SMART CAMP Authors
Kerwin Kwek Zeming, Rohan Vernekar, Mui Teng Chua, Kai Yun Quek, Greg Sutton, Timm Krüger, Win Sen Kuan, Jongyoon Han
Label‐Free Biophysical Markers from Whole Blood Microfluidic Immune Profiling Reveal Severe Immune Response Signatures
2021
SMART CAMP Authors
Kerwin Kwek Zeming, Ri Lu, Kai Lee Woo, Guoyun Sun, Kai Yun Quek, Lih Feng Cheow, Chia-Hung Chen, Jongyoon Han, and Shir Lynn Lim
Multiplexed Single-Cell Leukocyte Enzymatic Secretion Profiling from Whole Blood Reveals Patient-Specific Immune Signature
2021
SMART CAMP Authors
Conference Presentations
Wei-Xiang Sin, Narendra Suhas Jagannathan, Denise Bei Lin Teo, Faris Kairi, Dedy Sandikin, Ka-Wai Cheung, Yie Hou Lee, Rajeev J. Ram, Lisa Tucker-Kellogg, Michael E. Birnbaum
SMART CAMP Authors
2023
Nicholas Ng Zhi Heng, Kerwin Kwek Zeming, Kai Yun Quek, Francesca Loraine Lim, Yunxin Chen, Chin Ren Goh, Faye Cheung Ka Wai, Sin Wei Xiang, Michael E. Birnbaum, Jongyoon Han
SMART CAMP Authors
2023
Nicholas Tan Kwan Zen, Kerwin Kwek Zeming, Kai Yun Quek, Francesca Loraine Lim, Yunxin Chen, Chin Ren Goh, Nicholas Ng Zhi Heng, Michael E. Birnbaum, Jongyoon Han
SMART CAMP Authors
2023
Kerwin Kwek Zeming, Kai Yun Quek, Wei-Xiang Sin, Ka-Wai Cheung, Michael E. Birnbaum, Jongyoon Han
SMART CAMP Authors
2023
James P. B. Strutt (SMART), Meenubharathi Natarajan (SMART), Wei Xiang Sin (SMART), Elizabeth Lee (SMART), Paul W. Barone (MIT), Jacqueline M. Wolfrum (MIT), Rohan B. H. Williams (NTU), Scott A. Rice (NTU), Stacy L. Springs (MIT)
SMART CAMP Authors
2022
Wei-Xiang SIN (SMART), Denise TEO (SMART), Kevin S. LEE (Erbi Biosystems Inc), Harry LEE (Erbi Biosystems Inc), Narendra Suhas JAGANNATHAN (Duke-NUS), Rajeev RAM (MIT), Lisa TUCKER-KELLOGG (Duke-NUS), Michael BIRNBAUM (MIT)
SMART CAMP Authors
2022
Wei-Xiang SIN (SMART), Faye CHEUNG (SMART), Sandy LEE (A*STAR SIgN), Dedy SANDIKIN (SMART), Denise TEO (SMART), Faris KAIRI (SMART), Cheng-I WANG (A*STAR SIgN), Michael BIRNBAUM (MIT)
SMART CAMP Authors
2022
Kevin S. Lee (Erbi Biosystems Inc.), Wei-Xiang Sin (SMART), Michael Birnbaum (MIT)
SMART CAMP Authors
2022
Wei-Xiang Sin (SMART), Kevin S. Lee (Erbi Biosystems Inc.), Harry Lee (Erbi Biosystems Inc.), Michael Birnbaum (MIT)
SMART CAMP Authors
2022
Kevin S. Lee (Erbi Biosystems Inc, Wei-Xiang Sin (SMART), Harry Lee (Erbi Biosystems Inc.), Michael Birnbaum (MIT)
SMART CAMP Authors
2022
Bottleneck 1
There are no label-free methods of monitoring cell attributes during production (for rapid feedback), and it is not clear how predictive current attributes are.
Bottleneck 2
Processes are slow (weeks) and challenging to scale-out for autologous CAR T-cells; reagent innovations costly to evaluate for optimal manufacturing.
Goal 1
To identify rapid, (ideally) label-free CQAs for CAR T-cell potency and sterility.
Goal 2
To improve CAR-T production via deployment of new production technologiesand PATs.
